Yen Yun 4
4 · LIXTE BIOTECHNOLOGY HOLDINGS, INC. · Filed Jan 22, 2025
Insider Transaction Report
Form 4
Yen Yun
Director
Transactions
- Award
Options to Purchase Common Stock
2025-01-20+4,545→ 4,545 totalExercise: $2.33From: 2025-01-20Exp: 2030-01-20→ Common (4,545 underlying)
Holdings
- 10,000
Options to Purchase Common Stock
Exercise: $30.30From: 2021-06-30Exp: 2026-06-30→ Common (10,000 underlying) - 4,527
Options to Purchase Common Stock
Exercise: $2.37From: 2024-06-30Exp: 2029-06-30→ Common (4,527 underlying) - 3,333
Options to Purchase Common Stock
Exercise: $16.80From: 2018-08-04Exp: 2023-08-04→ Common (3,333 underlying) - 10,000
Options to Purchase Common Stock
Exercise: $2.37From: 2024-06-30Exp: 2029-06-30→ Common (10,000 underlying) - 5,786
Options to Purchase Common Stock
Exercise: $1.30From: 2024-09-30Exp: 2029-09-30→ Common (5,786 underlying) - 5,000
Options to Purchase Common Stock
Exercise: $32.10From: 2021-01-06Exp: 2026-01-06→ Common (5,000 underlying) - 5,263(indirect: By Sino-American Cancer FDD)
Warrants to Purchase Common Stock
Exercise: $57.00From: 2020-11-30Exp: 2025-11-30→ Common (5,263 underlying) - 833
Options to Purchase Common Stock
Exercise: $66.00From: 2019-05-22Exp: 2024-05-22→ Common (833 underlying) - 10,000
Options to Purchase Common Stock
Exercise: $7.45From: 2022-06-30Exp: 2027-06-30→ Common (10,000 underlying)
Footnotes (1)
- [F1]Effective January 20, 2025, the reporting person was granted stock options to purchase an aggregate of 4,545 shares vesting immediately. The grant was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.